Immune Tolerance Network (UM1 Clinical Trial Required)
Program description
The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Past awards
Federal awards made under Assistance Listing 93.855 in FY2022–FY2026, from USAspending.gov.
- Awards made
- 8,660
- FY2022–FY2026
- Total awarded
- $10.7B
- FY2022–FY2026
- Typical award
- $313.5K
- Middle half $158K–$713.2K
- States & territories
- 52
- with at least one award
Typical award is the median of FY2026 awards; half of awards fell between the quartiles shown.
| Year | Total awarded | Awards |
|---|---|---|
| FY2022 | $3.4B | 1,510 |
| FY2023 | $2.5B | 1,668 |
| FY2024 | $2.2B | 1,689 |
| FY2025 | $1.5B | 1,577 |
| FY2026 | $1.1B | 2,216 |
Where awards went
Top states by dollars, all years on record
- California$5.2B · 1,808 awards
- Massachusetts$3.7B · 1,329 awards
- New York$3.3B · 1,305 awards
- Washington$3.2B · 617 awards
- North Carolina$3.1B · 669 awards
Source: USAspending.gov award records for this assistance listing, which can fund more than one opportunity. This is history, not a guarantee: future award sizes, counts and eligible recipients may differ. Exact total for FY2022–FY2026: $10,718,465,457.
Contact
Division of Allergy, Immunology and Transplantation ITN_UM1@mail.nih.gov
ITN_UM1@mail.nih.gov